Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer

BACKGROUND: There are increasing reports of myasthenia gravis (MG) following oncological treatment with immune checkpoint inhibitors (ICIs). METHODS AND RESULTS: A 66-year-old man with stage 3A lung adenocarcinoma was treated with second weekly infusions of durvalumab, a programmed cell death ligand...

Descripción completa

Detalles Bibliográficos
Autores principales: Phua, Chun Seng, Murad, Ari, Fraser, Clare, Bray, Victoria, Cappelen-Smith, Cecilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871726/
https://www.ncbi.nlm.nih.gov/pubmed/33681778
http://dx.doi.org/10.1136/bmjno-2019-000028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871726/
https://www.ncbi.nlm.nih.gov/pubmed/33681778
http://dx.doi.org/10.1136/bmjno-2019-000028

Ejemplares similares